-
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
PharmaSources
April 01, 2024
ICP-189 is a potent and selective oral allosteric inhibitor of SHP2, developed by InnoCare for the treatment of solid tumors as a single agent and/or in combination with other antitumor agents.
-
InnoCare Releases 2023 Results and Business Highlights
PharmaSources
March 29, 2024
InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2023 annual results as of 31 December 2023.
-
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
PharmaSources
January 24, 2024
Jan. 24, 2024 - InnoCare Pharma announced today that the first pediatric patient has been dosed in clinical trial with its second.
-
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
PharmaSources
January 16, 2024
ICP-248 is a novel, orally bioavailable BCL2-selective inhibitor, which aims to treat hematologic malignancies as a monotherapy or in combination with other therapies.
-
InnoCare and Keymed Jointly Announce First Subject Dosed in Clinical Trial of CCR8 Monoclonal Antibody ICP-B05
PharmaSources
February 24, 2023
InnoCare Pharma and Keymed Biosciences that the first subject has been dosed in clinical trial of ICP-B05.
-
Chinese BTK Inhibitor Orelabrutinib Gone Global, What Other Drugs Have Been Ok'd Overseas in 2021
PharmaSources/Dopine
July 26, 2021
On July 13, InnoCare Pharma and Biogen made joint announcement that they have entered into an agreement on the license and cooperation of the BTK inhibitor Orelabrutinib.
-
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
PharmaSources
January 23, 2024
The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been approved by regulatory authorities for marketing in Hong Kong or Macao.
-
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
PharmaSources
January 17, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.
-
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PharmaSources
December 28, 2023
InnoCare Pharma announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S.
-
InnoCare Appoints Xin Fu as Chief Financial Officer
PharmaSources
December 18, 2023
InnoCare Pharma, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer.